ERBB2 and breast cancer: It usually responds poorly to endocrine therapy and human epidermal growth factor receptor 2 (HER2)-targeted therapy (Yagata, Kajiura & Yamauchi, 2011), so if TNBC and other BC subtypes (non-TNBC) are distinguishing before surgery, it can been early determined whether patients are suitable for neoadjuvant treatment and which strategy would be more effective and also plays an important role in improving survival (Zhang et al., 2021a).